MX2023001741A - Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor. - Google Patents

Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.

Info

Publication number
MX2023001741A
MX2023001741A MX2023001741A MX2023001741A MX2023001741A MX 2023001741 A MX2023001741 A MX 2023001741A MX 2023001741 A MX2023001741 A MX 2023001741A MX 2023001741 A MX2023001741 A MX 2023001741A MX 2023001741 A MX2023001741 A MX 2023001741A
Authority
MX
Mexico
Prior art keywords
compounds
pain
treatment
hydrated ketone
ketone inhibitors
Prior art date
Application number
MX2023001741A
Other languages
English (en)
Spanish (es)
Inventor
John Mulcahy
Hassan Pajouhesh
Dennis Monteleone
Xiang Zhou
Original Assignee
Siteone Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siteone Therapeutics Inc filed Critical Siteone Therapeutics Inc
Publication of MX2023001741A publication Critical patent/MX2023001741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023001741A 2020-08-14 2021-08-14 Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor. MX2023001741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063066012P 2020-08-14 2020-08-14
PCT/US2021/046054 WO2022036297A1 (en) 2020-08-14 2021-08-14 Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain

Publications (1)

Publication Number Publication Date
MX2023001741A true MX2023001741A (es) 2023-04-25

Family

ID=77693595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001741A MX2023001741A (es) 2020-08-14 2021-08-14 Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.

Country Status (12)

Country Link
US (1) US20230339958A1 (enExample)
EP (2) EP4196482B1 (enExample)
JP (2) JP2023537632A (enExample)
KR (1) KR20230051252A (enExample)
CN (1) CN116368139A (enExample)
AU (1) AU2021326546A1 (enExample)
BR (1) BR112023002659A2 (enExample)
CA (1) CA3188924A1 (enExample)
ES (1) ES3061196T3 (enExample)
IL (1) IL300626A (enExample)
MX (1) MX2023001741A (enExample)
WO (1) WO2022036297A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058214A1 (en) 2017-03-29 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University 11,13-modified saxitoxins for the treatment of pain
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
SMT202600064T1 (it) 2021-06-04 2026-03-09 Vertex Pharma Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
KR20260116140A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
KR20260116141A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료용 화합물 및 이의 고체 형태의 제조방법
KR20260118418A (ko) 2023-10-23 2026-07-30 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
AU2024393245A1 (en) 2023-12-07 2026-06-18 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
LU605402B1 (en) 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2760946C (en) 2009-05-07 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置
AU2016329201A1 (en) * 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
JP2020515611A (ja) * 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
EP3860714B1 (en) * 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain

Also Published As

Publication number Publication date
EP4647075A3 (en) 2026-01-14
EP4647075A2 (en) 2025-11-12
WO2022036297A1 (en) 2022-02-17
ES3061196T3 (en) 2026-03-31
EP4196482B1 (en) 2025-10-01
CN116368139A (zh) 2023-06-30
BR112023002659A2 (pt) 2023-05-02
AU2021326546A1 (en) 2023-04-13
CA3188924A1 (en) 2022-02-17
JP2023537632A (ja) 2023-09-04
US20230339958A1 (en) 2023-10-26
IL300626A (en) 2023-04-01
KR20230051252A (ko) 2023-04-17
EP4196482A1 (en) 2023-06-21
JP2026116909A (ja) 2026-07-14

Similar Documents

Publication Publication Date Title
BR112023002659A2 (pt) Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor
CL2020003304A1 (es) Oligonucleótidos para modular la expresión de scn9a
CL2024003258A1 (es) Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para tratar dolor
MX2023012725A (es) Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
CO2025015814A2 (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
CL2024004021A1 (es) Composiciones farmacéuticas que comprenden inhibidores de helicasa wrn
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
CO2025013134A2 (es) Inhibidores de kras
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CL2024002956A1 (es) Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo.
UY40234A (es) Compuestos heteroarilo para el tratamiento del dolor
UY40235A (es) Compuestos de heteroarilo para el tratamiento del dolor
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
PA8489501A1 (es) Antibioticos cetolidos
PA8598801A1 (es) Sales de los inhibidores triciclicos de las poli (adp-ribosa) polimerasas
CO2025009612A2 (es) Inhibidores de kif18a y usos de los mismos
PY2049213A (es) Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones
CL2022000458A1 (es) Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604)
ES2164899T3 (es) Uso de alcaloides de la clase lamellarina en metodos de tratamiento.
MX2025002807A (es) Compuestos bloqueadores del canal de sodio, derivados de los mismos y metodos de su uso
CL2025002035A1 (es) Compuestos moduladores de receptores de dopamina d3/d2
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
MX2022001722A (es) Tecnicas de sobremoldeo y articulos relacionados producidos a partir de las mismas.
MX2025013233A (es) Formas polimorficas y formulaciones de leriglitazona
AR126755A1 (es) Compuestos heterocíclicos y métodos de uso